Nordic Life Science Pipeline
Québec, Quebec, G1Y2T4, Canada
NCT Number: NCT02429206
In the general population, xerosis is often caused by external factors such as seasonal changes. In that case, the best way to relieve dry skin is to use a standard moisturizer. However, for those suffering of mobility problems due to age or paralysis (e.g., spinal cord injury, multiple sclerosis, Parkinson's, etc), xerosis is often severe and chronic because of the multiple causes (endogenous rather than exogenous ones) underlying such mobility impairment-related skin problems. This study is a double-blind, randomized study with positive control (active comparator) to assess the safety and efficacy of SQIN with CanSATs (Co-Activation of Natural Synergistically Acting Target-receptorS) technology on dry skin in patients suffering of paralysis.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Phase 2 / Phase 3
Québec, Quebec, G1Y2T4, Canada
Xerosis is a medical term for dry skin. When it results in skin that is scaly and itchy, the condition is called pruritus. This occurs when natural moisture is drawn out of the skin. The skin needs moisture to protect itself. The best way to relieve dry skin normally, for those suffering of seasonal dry skin problems, is to use standard moisturizers. However, for those suffering of mobility problems due to age or paralysis (spinal cord injury, multiple sclerosis, Parkinson's, Alzheimer's, muscular dystrophy, amputation, cerebral palsy, or other comparable disorders), xerosis becomes severe and chronic because of the multiple causes (endogenous metabolic problems and dysfunctions rather than exogenous ones). SQIN with CanSATs technology is designed to act upon multiple mechanisms for enhanced protecting, moisturizing, and repairing effects. Based upon preliminary evidence, SQIN with CanSATs technology can thus elicit significantly superior effects compared with standard, commercially available moisturizers.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Each patient will be asked to self-apply both creams (experimental vs positive control) on the right and left sides of their body (sides will be randomly assigned).
Other names: SQIN on one side - control cream on other side
Time frame: 14 days
Self-assessment of redness or itchiness problems during or after the treatment
Time frame: 14 days
Self-assessment (5-level score) of dry skin conditions before, during and after the treatment
Time frame: 14 days
Self-assessment (5-level score) of the elasticity level of the skin before, during and after the treatment
Nordic Life Science Pipeline Inc.
Other
Prospective, Double Blind, Randomized Phase II/III Study to Assess the Safety and Efficacy of SQIN™ on Xerosis in Adults Suffering of Mobility Impairment and/or Complete Paralysis Associated With Chronic Spinal Cord Injury.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06706050
Xerosis
Asan, Chungnumdo, South Korea
View Trial DetailsNCT04181177
Pathological Conditions, Signs and Symptoms, Pruritus
Cahors, France
View Trial DetailsNCT03497130
Itching, Pathological Conditions, Signs and Symptoms
Baltimore, Maryland, United States
View Trial DetailsNCT03093597
Dermatitis, Dry Skin; Eczema
Tucson, Arizona, United States
View Trial Details